It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
PEAK pseudokinases are molecular scaffolds which dimerize to regulate cell migration, morphology, and proliferation, as well as cancer progression. The mechanistic role dimerization plays in PEAK scaffolding remains unclear, as there are no structures of PEAKs in complex with their interactors. Here, we report the cryo-EM structure of dimeric PEAK3 in complex with an endogenous 14-3-3 heterodimer. Our structure reveals an asymmetric binding mode between PEAK3 and 14-3-3 stabilized by one pseudokinase domain and the SHED domain of the PEAK3 dimer. The binding interface contains a canonical phosphosite-dependent primary interaction and a unique secondary interaction not observed in previous structures of 14-3-3/client complexes. Additionally, we show that PKD regulates PEAK3/14-3-3 binding, which when prevented leads to PEAK3 nuclear enrichment and distinct protein-protein interactions. Altogether, our data demonstrate that PEAK3 dimerization forms an unusual secondary interface for 14-3-3 binding, facilitating 14-3-3 regulation of PEAK3 localization and interactome diversity.
PEAK pseudokinases are emerging disease targets, which regulate cell migration and proliferation through protein scaffolding. Here, the authors present the cryo-EM structure of the PEAK3/14-3-3 complex and reveal how 14-3-3 modulates PEAK3 localization and protein-protein interactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of California San Francisco, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Biophysics Graduate Program, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 University of California San Francisco, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
3 University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
4 University of California San Francisco, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Medical Scientist Training Program, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 University of Texas Southwestern Medical Center, Department of Molecular Biology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); Warsaw University of Life Sciences, Department of Biochemistry and Microbiology, Warszawa, Poland (GRID:grid.13276.31) (ISNI:0000 0001 1955 7966)
6 University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); J. David Gladstone Institutes, San Francisco, USA (GRID:grid.249878.8) (ISNI:0000 0004 0572 7110)
7 University of California San Francisco, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)